Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

A reproducibility study in pulmonary adenocarcinomas supports a revised classification

OncoAlert Round Up for September 1-7, 2023

Reducing stigma for lung cancer and other smoking-related respiratory diseases

Part 6: Which different PARP inhibitors are available

Part 7: Similarities and Differences

Part 8: How PARP inhibitors are being used now

Part 9: What PARP inhibitors mean for the future and what to look out for

Asia-Pacific Oncology Alliance

The Vietnam National Cancer Institute’s efforts in improving cancer care in Vietnam

Cancer control initiatives at the National Cancer Center Korea